A Dundalk-area man is the first person in Canada to receive a new, publicly funded treatment that better targets prostate cancer cells and is shown to prolong life.

Jan. 16, 2025 — Scientists have made 'exciting,' patient-friendly advances in developing a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs ... Tumor DNA in the Blood Can ...

Bayer’s TRK inhibitor Vitrakvi has been approved by the EMA, becoming the first therapy ... tumour types, and is more common in sarcomas, brain, kidney and thyroid cancers. Use of the drug ...

The biotech is also evaluating buparlisib’s use in solid tumors with so-called PIK3CA mutations, the group for which Piqray is approved for use in breast cancer. The Food and Drug Administration has ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

Study of 107,000 participants demonstrates regular aspirin use significantly reduces colorectal cancer risk, especially in ...

Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

Hundreds of FDA-approved drugs tested directly on a patient’s tumor sample. Could this be a gamechanger for cancer management ...

Cisplatin and etoposide are already used in chemotherapy ... with ovarian cancer, many relapse later and overall cure rates are improving only very slowly. These old drugs in a new regime will ...

Since two gene therapies were approved for sickle cell disease in late 2023, only a handful of patients have started the ...

Inspra (eplerenone tablets; Pfizer, Inc., New York, NY) is an aldosterone blocker that works by binding at the mineralocorticoid receptor. It has some similarities to the potassium-sparing ...

Roche is on course for a third indication for its fast-growing ophthalmic disease therapy Vabysmo ... 17 letters on a standard eye chart. Roche's drug was also comparable to Eylea on achieving ...